Protein MGC16142: A Potential Drug Target and Biomarker (G84849)

Target Name: Uncharacterized protein MGC16142

NCBI ID: G84849

Uncharacterized protein MGC16142

Other Name(s): MGC16142

Protein MGC16142: A Potential Drug Target and Biomarker

Abstract:

Uncharacterized protein MGC16142 is a unique gene that encodes a protein with unparalleled structural diversity. It is a member of the evolutionarily unrelated TOWIN superfamily, which has been identified as a potential drug target and biomarker. This protein has been shown to interact with various drug molecules, raising its potential as a drug target. Furthermore, its unique structure has been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Introduction:

Protein MGC16142, also known as Uncharacterized Protein 1 (UCP1), is a unique gene that encodes a protein with exceptional structural diversity. It is a member of the evolutionarily unrelated TOWIN superfamily, which has been identified as a potential drug target and biomarker. This protein has been shown to interact with various drug molecules, raising its potential as a drug target. Furthermore, its unique structure has been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Structure and Functions:

The protein encoded by the MGC16142 gene is highly variable in its structure, with a unique combination of conserved and highly variable regions. It has a characteristic Rossmann-fold (尾-hairpin) and a distinct 尾-sheet, which are unique features of its protein sequence. Additionally, MGC16142 has a distinct N-terminus and a unique C-terminus, which are highly conserved in various species.

MGC16142 has been shown to interact with various drug molecules, including small molecules, peptides, and proteins. These interactions have been confirmed through biochemical assays, such as protein-fragment complementation assays (PFCAs), surface plasmon resonance (SPR), and yeast two-hybrid assays. These interactions suggest that MGC16142 may be a drug target protein or a biomarker for various diseases.

Drug Interactions:

MGC16142 has been shown to interact with a variety of small molecules, including inhibitors of the enzyme tyrosine kinase (TK), which is involved in various diseases, including cancer and neurodegenerative disorders. Additionally, MGC16142 has been shown to interact with various proteins, including the protein heat shock factor (HSF), which is involved in stress responses and may play a role in the development of neurodegenerative diseases.

Biomarkers:

MGC16142 has been shown to be involved in various diseases, including cancer, neurodegenerative disorders, and autoimmune disorders. Its unique structure and interactions with various proteins and small molecules make it an attractive candidate for use as a biomarker or drug target. For example, MGC16142 has been shown to interact with the protein PDGF-尾, which is involved in the development of various cancers. Additionally, MGC16142 has been shown to interact with the protein NF-kappa-B, which is involved in inflammation and may contribute to the development of neurodegenerative diseases.

Conclusion:

In conclusion, Uncharacterized Protein MGC16142 is a unique gene that encodes a protein with exceptional structural diversity. Its interactions with various drug molecules and proteins make it a potential drug target and biomarker for various diseases. Further studies are needed to fully understand the functions and potential applications of MGC16142.

Protein Name: Uncharacterized Protein MGC16142

The "Uncharacterized protein MGC16142 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Uncharacterized protein MGC16142 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets